Abstract
The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998, 62 patients with NSCLC who had not received previous chemotherapy for advanced disease were enrolled in this study. 59 patients (22 stage IIIB and 37 stage IV) were eligible for the evaluation of efficacy and safety. S-1 was administered orally, twice daily, after meals. 3 dosages of S-1 were prescribed according to body surface area (BSA) so that they would be approximately equivalent to 80 mg m–2day–1: BSA < 1.25 m2, 40 mg b.i.d.; BSA≥1.25 but <1.5 m2; 50 mg b.i.d., and BSA≥1.5 m2: 60 mg b.i.d. One cycle consisted of consecutive administration of S-1 for 28 days followed by a 2-week rest period, and cycles were repeated up to 4 times. The partial response (PR) rate of the eligible patients was 22.0% (13/59); (95% confidence interval: 12.3–34.7%). A PR was observed in 22.7% (5/22) of the stage IIIB patients and 21.6% (8/37) of the stage IV patients. The median response duration was 3.4 months (1.1–13.7 months or longer). Grade 4 neutropenia was observed in one of the 59 patients (1.7%). The grade 3 or 4 toxicities consisted of decreased haemoglobin level in 1.7% of patients (1/59), neutropenia in 6.8% (4/59), thrombocytopenia in 1.7% (1/59), anorexia in 10.2% (6/59), diarrhoea in 8.5% (5/59), stomatitis in 1.7% (1/59), and malaise in 6.8% (4/59), and their incidences were relatively low. There were no irreversible, severe or unexpected toxicities. The median survival time (MST) of all patients was 10.2 months (95% confidence interval: 7.7–14.5 months), and the one-year survival rate was 41.1%. The MST of the stage IIIB patients was 7.9 months, and that of the stage IV patients was 11.1 months. The one-year survival rates of the stage IIIB and IV patients were 30.7% and 47.4%, respectively. S-1 was considered to be an active single agent against NSCLC. Further study of S-1 with other active agents is warranted. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ansfield FJ, Kallas GJ and Singson JP (1983) Phase I-II studies of oral Tegafur (Ftorafur). J Clin Oncol 1: 107–110
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger H, Brown CS and Griffin T (1999) Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485–493
Cutsem EV, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Seitz JF, Schölmerich J, Burger HU and Verweij J (2000) Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol 18: 1337–1345
Devita, Jr VT (1997) Principles & Practice of Oncology, Fifth Edition, pp. 858–911 Lippincott-Raven Publishers
Giller SA, Zhuk Ra and Lidak MY (1967) Analogs of pyrimidine nucleosides I. N1-(α-tetrahydrofuryl) derivatives of natural pyrimidine bases and their antimetabolites (in Russian). Dokl Akad Nauk SSSR 176: 332–335
Hara Y (1984) 5′-deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues. Jpn J Cancer Chemother 11: 2133–2143
Harris BE, Song R, Soong S and Diasio RB (1990) Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50: 197–201
Heggie GD, Sommadossi J-P, Cross DS, Huster WJ and Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203–2206
Hino M, Kudoh S, Furuse K, Hasegawa K, Takada M, Ichinose Y, Sugiura T and Niitani H (1996) Early phase II Study of S-1 in Patients with Non-Small-Cell Lung Cancer. Ann Oncol 7: 503
Hirata K, Horikoshi N and Aiba K (1999) pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clinical Cancer Research 5: 2000–2005
Ichinose Y, Takanashi N, Yano T, Asoh H, Yokoyama H, Tayama K, Hara N and Ohta M (1995) A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer. Cancer 75: 2677–2680
Ikenaka k, Shirasaka T, Kitano S and Fujii S (1979) Effect of uracil on metabolism of 5-fluorouracil in vitro. Jpn J Cancer Res (Gann) 70: 353–359
Japan Society for Cancer Therapy (1993) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy. J Jpn Soc Cancer Ther 28: 101–130
Kaplan EL and Meier P (1958) Nonparametric estimation from incomplete observations. Am Stat Assoc 53: 457–481
Keicho N, Saijo N, Shinkai T, Eguchi K, Sasaki Y, Tamura T, Sakurai M, Sano T and Hoshi A (1986) Phase II study of UFT in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 16: 143–146
Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA and Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. J Clin Oncol 7: 425–432
Moynihan T, Hansen R, Anderson T, Quebbeman E, Beatty P, Ausman R, Ritch P, Chitambar C and Vukelich M (1988) Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11: 461–464
Nakai Y, Furuse K, Ohta M, Yamaguchi Y, Fujii M, Asakawa M, Fukuoka M, Yoshida K and Niitani H (1994) Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study. Acta Oncologica 33: 523–526
Nakai Y, Saito J, Koinumaru S and Saijo Y (1999) A phase II trial of oral UFT and cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 18: 483a
Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M, Takeda C, Taguchi T, Terasawa T, Tominaga K, Furue H, Wakui A and Ogawa N (1985) Phase II study of 5′-deoxy-5-fluorouridine(5′DFUR) on patients with malignant cancer-Multi-institutional cooperative study. Jpn J Cancer Chemother 12: 2044–2051
Ota K, Taguchi T and Kimura K (1988) Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333–338
Richards F, Perry D, Goutsou M, Modeas C, Muchmore E, Rege V, Chahinian AP, Hirsh V, Poiesz B and Green MR (1991) Chemotherapy with 5-fluorouracil[5-FU] and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the Cancer and Leukemia Group B. Cancer 67: 2974–2979
Seifert P, Baker LH, Reed ML and Vaitkevicius VK (1975) Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 36: 123–128
Shirasaka T, Shimamoto Y and Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004–4009
Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Saito H, Okabe H, Oyama K, Takeda S, Unemi N and Fukushima M (1996a) Antitumor activity of 1M tegafur-0.4M 5-chloro-2,4-dihydroxypyridine-1M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602–2606
Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M (1996b) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7: 548–557
Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S and Nakao I (1997) Phase I study of S-1. Jpn J Cancer Chemother 24: 2253–2264
Tatsumi K, Fukushima M, Shirasaka T and Fujii S (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res (Gann) 78: 748–755
Unemi N, Harima K, Daidai Y, Fujiwara M and Fujii S (1971) Experimental studies of N1-(2′-tetrahydrofuryl)-5-fluorouracil(FT-207). Gan No Rinsho 17: 731–742
Vogelzang NJ (1984) Continuous infusion chemotherapy: a critical review. J Clin Oncol 2: 1289–1304
Weiden PL, Einstein AB and Rudolph RH (1985) Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. Cancer Treat Rep 69: 1253–1255
World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publ Geneva,
Yoshimori K, Yano T, Yoneda S, Kuba M, Ichinose Y, Kudoh S and Niitani H (1998) A phase II trial of UFT plus cisplatin in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17: 469a
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Kawahara, M., Furuse, K., Segawa, Y. et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85, 939–943 (2001). https://doi.org/10.1054/bjoc.2001.2031
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2031
Keywords
This article is cited by
-
Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301
BMC Cancer (2021)
-
Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer
Investigational New Drugs (2019)
-
Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer
General Thoracic and Cardiovascular Surgery (2019)
-
Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial
BMC Cancer (2017)
-
Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001
International Journal of Clinical Oncology (2017)